Using an automated technique to quantify amyloid plaque on PET scans in a patient’s native space can improve the detection of brain amyloid accumulation compared to traditional methods, according to a recent study published in the Journal of Nuclear Medicine.

Until now, the $168 million facility was producing limited amounts of Mo-99, a radioisotope used in approximately 85% of all Australian nuclear medicine procedures such as SPECT scans.

A team of German researchers has found a new class of radiopharmaceuticals capable of identifying 28 types of malignant tumors, imaging them with high uptake and image contrast.

The U.S. Pharmacopeia (USP) recently published a new chapter outlining minimum standards for preparing, compounding, dispensing and packaging sterile and non-sterile radiopharmaceuticals that are part of state-licensed activities.

The approach uses a linear electron accelerator and naturally-occurring molybdenum-100, eliminating the need for a nuclear reactor or enriched uranium.

Janesville, Wisconsin-based SHINE Medical Technologies has announced an agreement with the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), gaining exclusive rights over an innovation to produce lutetium-177 (Lu-177).

Researchers have combined a new imaging technique and imaging agent which utilizes a synthesized amino acid found in scorpion venom to help illuminate brain tumors during surgery.

The U.S. Nuclear Regulatory Commission (NRC) opened a 30-day public comment period seeking feedback on its draft document outlining training and experience requirements for administrating radiopharmaceuticals requiring a written directive.